We also tested the ability of anti-tau antibodies targeting MTBR/R’ (Gen2B) and the adjacent CT region (Gen2A) to reverse a persistent disruption of synaptic plasticity induced by tau-containing AD brain extracts. This evidence concerns the gene MAPT and Alzheimer disease.